Eli Lilly wins FDA approval for oral GLP-1 weight-loss drug Foundayo
The US Food and Drug Administration has approved Eli Lilly's orforglipron, branded Foundayo, as an oral once-daily treatment for obesity. The approval, confirmed on Wednesday, establishes Foundayo as only the second GLP-1 drug in pill form to reach the US market.
The timing places Lilly in direct competition with Novo Nordisk, whose oral Wegovy formulation received FDA approval in December 2025. Until recently, the GLP-1 obesity market was dominated by injectable products, and the emergence of two approved oral alternatives within months reshapes the competitive dynamics of the sector.
Foundayo can be taken once daily at any time, according to MarketWatch, removing the food-and-timing restrictions that have constrained some earlier oral GLP-1 candidates in clinical development. No pricing or launch timeline was included in the available disclosures.
For Lilly, the approval extends a portfolio that already includes the injectable tirzepatide franchise. The oral segment is widely seen as a potential growth driver because pill-form delivery may reduce barriers to initiation for patients and prescribers alike, though formulary placement and payer negotiations will shape actual uptake. Novo Nordisk's head start of roughly four months gives it an early positioning advantage, but Lilly's commercial infrastructure and physician relationships in the obesity space are well established.
